pain-management-internal-medicine-2019-posters-abstracts

34 / 46

Pain Management 2019 & Internal Medicine 2019 International Journal of Anesthesiology & Pain Medicine
ISSN: 2471-982X Page 72
JOINT EVENT
7th Edition of International Conference on
Pain Management
8th Edition of International Conference on
Internal Medicine &
Patient Care
&
March 25-26, 2019
Rome, Italy
Int J Anesth Pain Med 2019, Volume 5
DOI: 10.21767/2471-982X-C1-006
Long-term therapy with UDCA in the patients with alcoholic
liver disease
Nikolovska E, Miloshevski M, Chalovska-Ivanova V and Stardevola-Grivceva K
University Clinic of Gastroenterohepatology, Macedonia
Alcoholic steatosis (AS) and alcoholic hepatitits (AH)
is associated with inflammation, liver cell necrosis,
impired liver function, and progression to alcoholic
cirrhosis. Ursodeoxyholic acid (UDCA) has been reported
to be useful for patients with various liver diseases. In
the present study we investigated the effects of long-
term treatment UDCA in alcoholic liver disease (ALD).
53 patients with clinical, biochemical and histological
proven alcoholic liver disease were treated with UDCA
15±2 mg/kg/day for a period of 36 months. The patients
were selected in 3 groups: 21 with AS, 17 with AH and 15
with AC. Clinical symptoms (weakness, anorexia, weight
loss, nausea, vomiting, right upper quadrant abdominal
pain, jaundice, pruritus, fatigue), biochemical parameters
(y-glutamyl trans-peptidase, aminotransferases, alkaline
phosphates and serum bilirubin level) and histological
parameters were followed for a period of 3 years. UDCA
improved clinical symptoms in 51 out of 53 patients and
biochemical markers of cholestasis and hepatocellular
damage (GGTP, AST, ALT, ALP and serum bilirubin level)
in 46 out of 53 patients. The beneficial effect of UDCA on
the liver histology was assessed in 29 out of 53 patients
after minimumperiod of 12months of therapy commonly
in the patients group with AH and AS. Improvement
was found only in 12/53 patients with ALD, but not in
the patients group with alcoholic liver cirrhosis. Our
results strongly suggest that long-term treatment with
UDCA improves biochemical and clinical parameters in
alcoholic liver disease. Histological improvements was
partial and in minority of patients. The use of UDCA in
the treatment of ALD appears to be safe and without side
effects in our patients group.